The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of atezolizumab (A) + carboplatin (C) + pemetrexed (P) + bevacizumab (B) in pts with stage IV non-squamous non-small cell lung cancer (NSq-NSCLC): Big Ten Cancer Research Consortium Study LUN 17-139.
 
Fatemeh Ardeshir-Larijani
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Loxo (Inst); Merck Serono (Inst); Merit, Inc. (Inst); Tesaro (Inst)
 
Sandra K. Althouse
No Relationships to Disclose
 
Ticiana Leal
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; BeyondSpring Pharmaceuticals; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Debiopharm Group; EMD Serono; Genentech; Genentech; InvisionFirst Lung; Jazz Pharmaceuticals; Lilly; Merck; Merck; Merck; Novocure; Takeda
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Genentech; Merck; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Takeda; Takeda
(OPTIONAL) Uncompensated Relationships - Mirati Therapeutics
 
Lawrence Eric Feldman
Research Funding - BrightPath Biotheraputics; E.R. Squibb Sons, LLC (Inst); Genentech (Inst); Merck (Inst); Roche (Inst); Soligenix (Inst)
 
Taher Abu Hejleh
No Relationships to Disclose
 
Malini Patel
Honoraria - Bayer
 
Ryan D. Gentzler
Honoraria - Rockpointe CME; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Astra Zeneca; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Helsinn Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Adam Ryan Miller
No Relationships to Disclose
 
Nasser H. Hanna
Honoraria - UpToDate
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck KGaA (Inst)
Other Relationship - BeyondSpring Pharmaceuticals; BeyondSpring Pharmaceuticals